Skip to main content
Premium Trial:

Request an Annual Quote

Rick Silva, Tom Smerdon, Kate Tallman, Kathe Zaslow, Arlen Meyers, Paul Allenza

The Technology Transfer Office for the University of Colorado system has made several staff changes: Rick Silva has been named director of technology transfer at the UC Denver Health Sciences Center; Tom Smerdon is director of licensing and new business development; Kate Tallman is director of technology transfer for the Boulder and Colorado Springs campuses; and Kathe Zaslow has been named director of intellectual property operations.
In addition, Arlen Meyers, a professor in the department of otolaryngology at the University of Colorado Health Sciences Center, has been appointed as the academic director of the Bard Center Bioentrepreneurship Program.

Paul Allenza has been tapped as director for the University of Maryland’s Biotechnology Research and Education Program, an initiative dedicated to the research, education, and development of biotechnology products and processes for companies in Maryland.
Allenza previously spent 13 years with chemical firm FMC Corporation, first as senior research manager and then senior manager of technology acquisition and licensing at the company's research facility in Princeton, NJ.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.